Skip to Content

Ixekizumab

In the US, Ixekizumab (ixekizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Plaque Psoriasis.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AC13

CAS registry number (Chemical Abstracts Service)

1143503-69-8

Chemical Formula

C6492-H10012-N1728-O2028-S46

Molecular Weight

146190

Therapeutic Categories

Immunomodulator

Interleukin Inhibitor

Chemical Name

Immunoglobulin G4-kappa, anti-[Homo sapiensIL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody;gamma4 heavy chain (1-445) [humanized VH (Homo sapiensIGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiensIGHG4*01 hinge S10>P (227 (WHO)

Foreign Names

  • Ixekizumabum (Latin)
  • Ixekizumab (German)
  • IxĂ©kizumab (French)
  • Ixekizumab (Spanish)

Generic Names

  • Ixekizumab (OS: USAN, JAN)
  • LY2439821 (IS)
  • UNII-BTY153760O (IS)

Brand Name

  • taltz
    Eli Lilly and Company, United States

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide